NeoImmuneTech
NeoImmuneTech is a clinical-stage biopharmaceutical company developing T cell-centered immunotherapies led by NT-I7 (a long-acting IL-7 fusion protein), with a pipeline spanning oncology combinations, rare immune deficiencies, and direct commercialization of Endari for sickle cell disease in North America.
- Company typePublic
- Founded2014
- HeadquartersSeongnam, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeoImmuneTech does
NeoImmuneTech, Inc. is a clinical-stage biopharmaceutical company founded in January 2014 and headquartered in Rockville, Maryland, with a wholly-owned Korean subsidiary (NeoImmuneTech Co., Ltd., established August 2019) and a Poland subsidiary (May 2024). The company is publicly listed on Korea Exchange KOSDAQ (ticker 950220) since March 2021, trading as Depositary Receipts at a 1:5 ratio. It develops T cell-centered immunotherapeutics for cancer and infectious diseases, anchored by NT-I7 (efineptakin alfa), a long-acting interleukin-7 fusion protein built on Genexine-licensed HyFc technology that functions as a T cell amplifier — clinical data show up to 4-fold increases in CD4+/CD8+ T cells and up to 50-fold increases in stem-cell memory CD8+ T cells. The pipeline extends through the proprietary NEOBASE heterodimer Fc platform for bispecific antibodies and preclinical candidates NT2020 (PROTAC-based T cell activator), NT3020 (CD3xTAA T cell engager), and NT5010 (eTreg depletor for tumor microenvironment modification). NT-I7 has secured four FDA and two EMA Orphan Drug Designations across Acute Radiation Syndrome, glioblastoma, pancreatic cancer, PML, and ICL.
The company operates a dual revenue model. The first stream is out-licensing NT-I7 and pipeline assets to global pharmaceutical partners — Roche (TECENTRIQ combinations in NSCLC and high-risk skin cancer), Merck (KEYTRUDA combinations in solid tumors), Bristol Myers Squibb (OPDIVO combinations in gastric cancer), and Immunocore (KIMMTRAK/ImmTAC TCR combinations) — generating upfront payments, development milestones, and royalties. The second stream is direct commercialization of Endari (FDA-approved L-glutamine oral powder for sickle cell disease) in the United States, its territories, and Canada, secured through a December 2025 License and Exclusive Distribution Agreement with Emmaus Life Sciences, with US sales launched in June 2026 after obtaining Maryland state licensing in May 2026. Endari targets an estimated ~100,000 US sickle cell patients.
Customers span large pharmaceutical partners (co-development collaborators), academic medical centers including MD Anderson, Mayo Clinic, Washington University School of Medicine in St. Louis, UCSF, and NIH/NIAID (clinical trial collaborators and BARDA program participants), and — via the Endari franchise — sickle cell disease patients and payers in the North American market. Capital structure includes a KOSDAQ IPO (March 2021), a ~53.2 billion KRW (~$39M USD) rights offering and public offering in September 2025, and a 5-to-1 stock consolidation effective May 2026; ownership ties to Genexine (original NT-I7 licensor) and Emmaus Life Sciences (Endari partner with equity stake) remain material.
NeoImmuneTech firmographics
Firmographics- Name
- NeoImmuneTech
- Legal name
- NeoImmuneTech, Inc.
- Website
- https://neoimmunetech.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NeoImmuneTech is a clinical-stage biopharmaceutical company developing T cell-centered immunotherapies led by NT-I7 (a long-acting IL-7 fusion protein), with a pipeline spanning oncology combinations, rare immune deficiencies, and direct commercialization of Endari for sickle cell disease in North America.
- Ownership category
- akta.pro rank
NeoImmuneTech industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where NeoImmuneTech is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
NeoImmuneTech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Endari (L-glutamine oral powder) product sales: NeoImmuneTech directly commercializes Endari, an FDA-approved sickle cell disease treatment, in the United States, its territories, and Canada following a License and Exclusive Distribution Agreement with Emmaus Life Sciences (signed December 2025, effective Q2 2026). The company also holds rights to generic equivalents and manages pricing strategy, brand operations, and generic (AG) utilization decisions for the North American market. Emmaus receives upfront payments and ongoing royalties on product sales.
- Out-licensing and co-development fees (NT-I7 and pipeline): NeoImmuneTech generates revenue through licensing agreements with global pharmaceutical companies for co-development and commercialization of NT-I7 and other pipeline assets. Partners include Roche (TECENTRIQ combinations), Merck (KEYTRUDA combinations), Bristol Myers Squibb (OPDIVO combinations), and others. Revenue streams include upfront payments, milestone payments tied to clinical/regulatory achievements, and royalties on product sales.
- Royalties from Endari distribution agreement: Under the licensing arrangement with Emmaus Life Sciences, Emmaus pays NeoImmuneTech royalties based on Endari product sales in North America, in addition to upfront payments.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
NeoImmuneTech product offering
Product offeringCore offering
NeoImmuneTech is a clinical-stage biopharmaceutical company that develops and commercializes T-cell-centered novel immunotherapeutics, centered on NT-I7 (efineptakin alfa), a long-acting interleukin-7 fusion protein that amplifies T-cell numbers and function for cancer and infectious disease treatment. The company also directly commercializes Endari (L-glutamine oral powder), an FDA-approved sickle cell disease treatment, in North America under a licensing agreement with Emmaus Life Sciences.
Product overview
NeoImmuneTech operates as a T-cell focused immunotherapy company with a pipeline centered on its core platform technology and multiple therapeutic programs. The core product is NT-I7 (efineptakin alfa), a long-acting interleukin-7 fusion protein that functions as a T-cell amplifier, combined with proprietary platform technologies including the NEOBASE heterodimer Fc platform for bispecific antibody development. The company is expanding into commercialized products through the acquisition of Endari distribution rights for sickle cell disease treatment in North America. The development pipeline includes NT2020 (T-cell Activator using PROTAC), NT3020 (T-cell Engager), and NT5010 (TME Modifier), covering multiple T-cell focused therapeutic approaches for cancer and infectious diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- NT-I7 (efineptakin alfa) Long-acting human interleukin-7 (rhIL-7-hyFc) fusion protein functioning as a T-cell amplifier that enhances T-cell numbers and immunological function by promoting proliferation and survival of naive and memory T-cells. Indicated for cancer immunotherapy (solid tumors and hematologic malignancies in combination with checkpoint inhibitors, CAR-T, TCR therapies) and infectious diseases including PML, ICL, and ARS.
- Endari (L-glutamine oral powder) FDA-approved (July 2017) prescription L-glutamine oral powder for treating sickle cell disease in patients five years and older. Demonstrated 25% reduction in sickle cell crises and 33% decrease in hospitalizations in clinical studies. Distributed in the United States, its territories, and Canada following a License and Exclusive Distribution Agreement with Emmaus Life Sciences.
- NEOBASE Platform Proprietary next-generation heterodimer Fc platform technology for developing bispecific antibodies and multi-specific antibodies with enhanced structural stability and immune response promoting capabilities. Enables flexible arrangement of various antigen-targeting sequences and is currently used in NT3020 (T-cell engager) development.
- NT2020 (T-cell Activator)
Quantifiable outcome
- 25% reduction in sickle cell crises; 33% decrease in hospitalizations (Endari, FDA-approved 2017)
- +6 more outcomes
Companies that use NeoImmuneTech
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
NeoImmuneTech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
NeoImmuneTech partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered major and core.
- ImmunocoremajorJoint research collaboration evaluating NT-I7 with Immunocore's ImmTAC platform (KIMMTRAK/tebentafusp) for TCR-based cancer immunotherapy. Research results presented at ASCO 2026, demonstrating that IL-7 enhances ImmTAC-mediated tumor killing, improves T cell fitness (increased naive/stem-like T cells, decreased exhaustion markers), and increases T cell-mediated IFNγ secretion. Immunocore is a NASDAQ-listed UK-based biotech (~$400M annual revenue, ~$800M cash) and pioneer of TCR-based cancer therapy with KIMMTRAK.
- Emmaus Life SciencescoreLicense and Exclusive Distribution Agreement granting NeoImmuneTech exclusive rights to market, sell, and distribute Endari (FDA-approved sickle cell disease treatment) and related generic equivalents in the United States, its territories, and Canada. Emmaus receives upfront payment and ongoing royalties. The agreement aims to expand commercialization beyond the US's mature market into regions with greater growth potential. Implementation expected Q2 2026. In June 2026, the agreement was further optimized with some payment obligations converted to equity investment, minimizing cash outflow and aligning incentives between both parties.
- RochecoreCo-development agreement for TECENTRIQ (atezolizumab) and NT-I7 combination therapy targeting non-small cell lung cancer (NSCLC) (NIT-119, IND approved January 2020). Also covers high-risk skin cancer combination (IND initiated April 2018). Roche is a major global pharmaceutical company providing its PD-L1 checkpoint inhibitor for combination clinical trials with NT-I7.
- Bristol Myers Squibb (BMS)coreCo-development agreement for OPDIVO (nivolumab) and NT-I7 combination therapy targeting gastric cancer, initiated January 2020. Combines BMS's PD-1 checkpoint inhibitor with NT-I7 for immuno-oncology applications.
- Merck (MSD)coreCo-development agreement for KEYTRUDA (pembrolizumab) and NT-I7 combination therapy targeting solid tumors, initiated December 2019. Combines Merck's PD-1 checkpoint inhibitor with NT-I7's T cell amplification technology across multiple cancer indications.
- GenexinecoreLicense-in agreement from Genexine for NT-I7 (efineptakin alfa, rhIL-7-hyFc) in the Americas and Europe, established June 2015. NeoImmuneTech acquired rights to develop and commercialize NT-I7 in these territories. Additional co-development collaboration for head and neck cancer triple combination (NT-I7 + GX-188E + KEYTRUDA) with Phase 2 expansion cohort approval in January 2024. Genexine is a Korean biopharmaceutical company (GX-I7 is the Korean development designation).
- NIH / NIAID (National Institute of Allergy and Infectious Diseases)majorContract for ARS (Acute Radiation Syndrome) treatment development signed December 2022 with NIAID. Collaboration involves preclinical animal model studies for NT-I7 as an ARS countermeasure, supporting NeoImmuneTech's BARDA BAA program participation. NIAID is part of the US National Institutes of Health.
- MD Anderson Cancer CentermajorClinical trial collaboration and research partnership with MD Anderson Cancer Center for NT-I7 development. MD Anderson is one of the world's leading cancer centers, providing clinical research capabilities and scientific expertise for NT-I7 clinical programs.
- UCSF (University of California, San Francisco)majorResearch collaboration with UCSF for NT-I7 clinical development. Scientific Advisory Board member Dr. Hyunseok Kang (강현석) is a professor at UCSF Department of Oncology and conducts head and neck cancer clinical research with NT-I7 monotherapy (NIT-115).
- Washington University School of Medicine in St. LouismajorInvestigator-initiated trial collaboration for NIT-126 (CD19 CAR-T + NT-I7 for LBCL) and NIT-112 (CAR-T + NT-I7). Led by Zachary D. Crees and John F. DiPersio at Washington University, a leading institution in CAR-T cell therapy research.
Scale indicators9 records
Recent moves10 records
Expansion highlights6 records
NeoImmuneTech competitors and assessment
Company assessmentDirect peers
- Adaptimmune Therapeutics: Clinical-stage biotech developing engineered TCR-T cell therapies for solid tumors (e.g., Tecelra for synovial sarcoma). Comparable to NeoImmuneTech in its T cell-centered immuno-oncology focus and combination-therapy development model with checkpoint inhibitors.
- Immunocore: NASDAQ-listed UK biotech ($400M revenue, KIMMTRAK/tebentafusp) pioneering TCR-based cancer immunotherapy. Direct NT-I7 combination collaborator and a peer in TCR-driven T cell amplification, with overlapping scientific advisors and joint ASCO 2026 presentations.
- Allogene Therapeutics: Clinical-stage biotech developing allogeneic CAR-T cell therapies for hematologic malignancies and solid tumors. Directly comparable as a T cell therapy peer focused on improving CAR-T persistence and broadening access - the same clinical problem NT-I7's CAR-T combination programs (NIT-126, NIT-128) aim to address.
- Genexine: Korean biopharmaceutical company that originally developed and licensed-out NT-I7 (known as GX-I7 in Korea) to NeoImmuneTech for the Americas and Europe. Direct counterparty for the core asset and Chairman-level overlap; comparable as a clinical-stage cytokine/immunomodulator developer with parallel geographic rights to NT-I7.
Emerging players
- Zymeworks: Biotech developing bispecific and multifunctional antibody therapeutics using its proprietary Azymetric and EFECT platforms. Closely comparable platform-technology peer to NeoImmuneTech's NEOBASE heterodimer Fc platform for bispecific antibody development.
- Cullinan Oncology: Clinical-stage oncology company developing T cell engagers (e.g., CLN-978, CD19xCD3) and immune-modulating therapeutics. Comparable as an emerging immuno-oncology player with T cell engager technology that intersects with NeoImmuneTech's NT3020 bispecific program.
- Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated cytokine-based immunotherapies (e.g., IL-2, IL-12 prodrugs) for oncology. Comparable as a small-cap peer using engineered cytokines to amplify T cell responses in the tumor microenvironment, similar mechanistic approach to NT-I7.
- Compass Therapeutics: Clinical-stage biotech with bispecific antibody programs (CTX-009, CTX-1121) targeting oncology. Comparable to NeoImmuneTech in developing T cell-engaging bispecific antibodies and combination immunotherapies in solid tumors.
Broad incumbents
- Bristol Myers Squibb: Global pharma with leading checkpoint inhibitor (Opdivo), CAR-T franchises (Breyanzi, Abecma), and broad T cell immunotherapy portfolio. Both a direct collaboration partner (NT-I7 + Opdivo in gastric cancer) and a broad incumbent competitor with internal T cell programs.
- Regeneron Pharmaceuticals: Major US biopharma with deep immuno-oncology presence (Libtayo PD-1 antibody) and cytokine-based therapeutic platforms (REGN-COV antibodies). Comparable as an incumbent developing T cell-targeted combination therapies and as a potential large-pharma partner/competitor for combination strategies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
NeoImmuneTech social profiles
Digital presenceNeoImmuneTech financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeoImmuneTech leadership team
Management profileNumber of profiles
Profiles4 records
NeoImmuneTech subsidiaries and ownership
Company hierarchySubsidiaries1 record
NeoImmuneTech funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeoImmuneTech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeoImmuneTech
What does NeoImmuneTech do?
NeoImmuneTech is a clinical-stage biopharmaceutical company that develops and commercializes T-cell-centered novel immunotherapeutics, centered on NT-I7 (efineptakin alfa), a long-acting interleukin-7 fusion protein that amplifies T-cell numbers and function for cancer and infectious disease treatment. The company also directly commercializes Endari (L-glutamine oral powder), an FDA-approved sickle cell disease treatment, in North America under a licensing agreement with Emmaus Life Sciences.
Is NeoImmuneTech a public or private company?
NeoImmuneTech is a public company. It is classified as public and is currently operating.
When was NeoImmuneTech founded?
NeoImmuneTech was founded in 2014. It employs 11 to 50 people.
Where is NeoImmuneTech based?
NeoImmuneTech is headquartered in Seongnam, South Korea, in the Asia region.
How does NeoImmuneTech make money?
Three revenue lines are on record. Endari (L-glutamine oral powder) product sales are the primary driver. The others are out-licensing and co-development fees (NT-I7 and pipeline) and royalties from Endari distribution agreement.
Who are NeoImmuneTech's main competitors?
Direct peers on record are Adaptimmune Therapeutics, Immunocore, Allogene Therapeutics and Genexine. Emerging players are Zymeworks, Cullinan Oncology, Werewolf Therapeutics and Compass Therapeutics. Broad incumbents are Bristol Myers Squibb and Regeneron Pharmaceuticals.
Does NeoImmuneTech have an API?
No public API is recorded for NeoImmuneTech.
What industry is NeoImmuneTech in?
NeoImmuneTech's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.